Rigel Pharmaceuticals, Inc. (RIGL)
47.84
+0.34
(+0.72%)
USD |
NASDAQ |
Sep 02, 11:33
Rigel Pharmaceuticals Research and Development Expense (Annual) : 33.30M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 33.30M |
| December 31, 2024 | 23.38M |
| December 31, 2023 | 24.52M |
| December 31, 2022 | 60.27M |
| December 31, 2021 | 65.24M |
| December 31, 2020 | 60.10M |
| December 31, 2019 | 52.88M |
| December 31, 2018 | 46.90M |
| December 31, 2017 | 46.27M |
| December 31, 2016 | 63.45M |
| December 31, 2015 | 62.82M |
| December 31, 2014 | 67.70M |
| December 31, 2013 | 75.33M |
| December 31, 2012 | 78.78M |
| Date | Value |
|---|---|
| December 31, 2011 | 69.35M |
| December 31, 2010 | 64.39M |
| December 31, 2009 | 90.74M |
| December 31, 2008 | 109.67M |
| December 31, 2007 | 70.36M |
| December 31, 2006 | 56.97M |
| December 31, 2005 | 52.04M |
| December 31, 2004 | 48.52M |
| December 31, 2003 | 41.65M |
| December 31, 2002 | 43.35M |
| December 31, 2001 | |
| December 31, 2000 | |
| December 31, 1999 | |
| December 31, 1998 | 8.305M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Ironwood Pharmaceuticals, Inc. | 93.26M |
| Cytokinetics, Inc. | 405.90M |
| Perspective Therapeutics, Inc. | 70.96M |
| Capricor Therapeutics, Inc. | 83.50M |
| ACADIA Pharmaceuticals, Inc. | 328.80M |